elio plasma resolve

A focused liquid biopsy assay

elio PLASMA RESOLVE

Biomarker analysis and discovery for research

The PGDx elio™ plasma resolve assay evaluates a targeted panel of 33 well-characterized cancer genes using circulating tumor DNA. Get rapid, accurate results from low DNA input blood specimens.

4 – 5 Day sample-to-result turnaround time

Automated bioinformatics ensure consistent, high-quality results

High concordance to tissue

Accurately detects SNVs, indels, amplifications, translocations, and MSI

Focused assay

Identifies variants in 33 full coding genes across multiple cancer types with approved therapies or in professional guidelines

End-to-end kitted solution

Utilizing a robust turn-key bioinformatics pipeline with 30,000x sequencing coverage that keeps data and reporting in-house

elio PLASMA RESOLVE

Product overview

Benefits of the PGDx focused liquid biopsy assay

A sample-to-answer liquid biopsy solution

PGDx elio plasma resolve is a pan solid tumor NGS liquid biopsy assay that identifies key genomic alterations and guideline-supported biomarkers with high accuracy and sensitivity. It features proprietary methods for detecting microsatellite instability (MSI), as well as complex structural alterations and amplifications.

Backed by robust bioinformatics

PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab to provide timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.

Gene Panel

SEQUENCE MUTATION ANALYSIS (33 Genes)
AKT1
BRAF
CD274
EZH2
KRAS
PDGFRA
RET
ALK
BRCA1
CDH1
FGFR1
MET
PIK3CA
ROS1
APC
BRCA2
CSF1R
FGFR2
MYC
POLD1
TP53
ARID1A
BRIP1
EGFR
HRAS
NRAS
POLE
ATM
CCND1
ERBB2
KIT
NTRK1
RAF1
COPY NUMBER VARIATION (8 Genes)
CCND1
MYC
CD274
FGFR2
EGFR
ERBB2
KIT
MET
TRANSLOCATIONS (5 Genes)
ALK
FGFR2
NTRK1
RET
ROS1
TECHNICAL INFORMATION
elio plasma resolve product specs

PGDx elio plasma resolve evaluates a targeted panel of 33 well-characterized cancer genes. Analyses for sequence mutations or rearrangements can be performed together or separately, depending on the specific alterations of interest. Get the technical specifications:

Resources

CUSTOMER PORTAL
Review technical documents & sample reports
SUPPORT
Get help now

Start using elio plasma resolve